Clinical Characteristics, Rescue Treatments, Health Resources Utilization, and Medical Costs Associated with Chinese Chronic Hepatitis B Patients with Drug Resistance to Neucleot(S)IDE Analogues: A Retrospective Cohort Study

Y. Xu,H. Zhou,W. Chen,Y. Chen,H. Zhan,G. Gong

DOI: https://doi.org/10.1016/j.jval.2018.04.575

IF: 5.156

2018-01-01

Value in Health

Abstract:To describe the clinical characteristics, rescue treatment, and medical costs associated with CHB patients with drug resistance to NA. This retrospective cohort study identified a cohort of CHB patients with gene test for drug resistance from 2008 to 2016 in a Chinese tertiary care liver clinic. The medical and billing records associated with the included patients during the follow-up (from the diagnosis of drug resistance to December 31, 2016) were the data source. Descriptive statistical methods were used to summarize the collected data. The included patients were stratified by the rescue treatment regimen for the comparisons of measured outcomes including annual health resources utilization and annual medical costs. 117 patients were included for analysis. The included patients with developed drug resistance to NA were characterized with young age (mean:41.0+/-11.3 years),prevalent male gender (81.2%), evenly distributed by residence in urban and rural areas, and highly prevalent drug resistance gene (rtM204) for lamivudine (70.9%). The main rescue treatment regimens included entecavir (40.0%), lamivudine plus adefovir (23.0%), tenofovir (12.0%), and entecavir plus adefovir (14.0%) in the included 100 (85.5%) patients received rescue treatments. Unadjusted comparisons observed that the rescue treatment group was associated with significantly more annual outpatient clinic visits(4.7+/-3.6 vs. 2.6+/-2.6, p=0.011)and higher outpatient medical costs (median:¥6,403 vs. ¥613,p<0.001). Multiple generalized linear regression analysis with adjusting patient baseline characteristics confirmed the higher outpatient medical costs associated with rescue treatment (coefficient 1.385, p<0.001). Entecavir was the main rescue treatment in a Chinese CHB cohort with drug resistance mainly to lamivudine. The higher outpatient medical costs associated with rescue treatment may factor more active disease management for CHB.